Sales rose 66% to $86.3 million from $52 million.

Copley recognized nonrecurring charges of $2.9 million, or 16 cents a share, related to Hoechst Celanese Corp.'s $546 million acquisition of a 51% stake in a tender offer last October.

In the year-earlier quarter, Copley reported net income of $4 million, or 21 cents a share.

It didn't take any charge for that litigation.

Copley Pharmaceutical Inc. reported a fiscal fourth-quarter net loss of $8.5 million, or 45 cents a share, reflecting the costs of a drug-product recall and other nonrecurring charges.

In the year-earlier quarter, Copley had one-time charges of $1.8 million for litigation settlement and $1.8 million for costs of collaborating on research with another company.

Hoechst Celanese is a unit of Germany's Hoechst AG.

In Nasdaq Stock Market trading yesterday, Copley stock rose 50 cents, or 2%, to close at $25 a share.

Copley said it can't estimate the costs of litigation related to the recall, which has generated a number of lawsuits, including some alleging that albuterol users died from using the inhalant.

For the year ended Jan. 31, Copley reported net income of $6.4 million or 34 cents a share, down 48% from $12.3 million or 83 cents a share, the year before.

This year, besides the recall, Copley also took charges of $7.3 million, or 40 cents a share, to settle shareholder litigation related to a 1991 repurchase of shares.

Copley, a maker of generic pharmaceuticals, said revenue for the quarter rose 15% to $21.7 million from $18.8 million.

Copley said that without the nonrecurring charges, profit would have been $5.9 million, or 31 cents a share, in the 1994 quarter.

The recall cost $8 million before taxes.

Copley said its recall of albuterol, an asthma medication that was contaminated with bacteria, reduced net income for the quarter ended Jan. 31 by $4.8 million, or 26 cents a share.

